Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases
- 28 February 2011
- journal article
- review article
- Published by Elsevier BV in Journal of Immunological Methods
- Vol. 365 (1-2), 1-7
- https://doi.org/10.1016/j.jim.2010.12.001
Abstract
No abstract availableThis publication has 80 references indexed in Scilit:
- Primary immunodeficiencies: 2009 updateJournal of Allergy and Clinical Immunology, 2009
- In VivoDelivery of Antisense MORF Oligomer by MORF/Carrier Streptavidin NanoparticlesCancer Biotherapy & Radiopharmaceuticals, 2009
- Nonaminoglycoside compounds induce readthrough of nonsense mutationsThe Journal of Experimental Medicine, 2009
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicalsCurrent Opinion in Allergy and Clinical Immunology, 2008
- Pyogenic Bacterial Infections in Humans with MyD88 DeficiencyScience, 2008
- Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomersVirology, 2008
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic MiceAmerican Journal of Human Genetics, 2008
- Propionic and Methylmalonic Acidemia: Antisense Therapeutics for Intronic Variations Causing Aberrantly Spliced Messenger RNAAmerican Journal of Human Genetics, 2007
- Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotidesProceedings of the National Academy of Sciences of the United States of America, 2007